Back to School: How biopharma can reboot drug development. Access exclusive analysis here
According to ENZ, the judge has ruled that the patent portion of the suit was "anticipatory,"
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury